Worldwide,
gastric cancer despite declining incidence remains one of
the most common malignancies and a leading cause of cancer
death. Although in the USA only 22,700 new cases are expected
in 2001 real case-mortality remains high indicating little
progress in the treatment of diagnosed gastric cancer. However,
hopes for an improved patient outcome provides a most recent
report from USA.[1] This large, carefully monitored, randomized
trial is clinically important because up until now there
was no credible evidence for the effectiveness of adjuvant
treatment after gastric resection for cancer.[2-4] |
|